Results of Raltegravir plus combination antiretroviral therapy in early HIV infection

(Mary Ann Liebert, Inc./Genetic Engineering News) Addition of the integrase strand transfer inhibitor raltegravir (RAL) to standard antiretroviral therapy (ART) in ART-naive patients with early HIV infection was not associated with a difference in the quantity of HIV DNA, residual virus in the blood, or CD4+ T-cells containing replication-competent virus, according to a new study published in BioResearch Open Access.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news